ASSESSING THE ACCURACY OF A LARGE OBSERVATIONAL REGISTRY OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

被引:7
|
作者
Nguyen, Vuong [1 ]
Leung, King Fai Calvin [1 ]
Nguyen, Chu Luan [1 ]
Squirrell, David [2 ]
Essex, Rohan [3 ]
Arnold, Jennifer [4 ]
Young, Stephanie [5 ]
Barthelmes, Daniel [1 ,6 ]
Gillies, Mark [1 ]
机构
[1] Univ Sydney, Save Sight Inst, Sydney Med Sch, Discipline Ophthalmol, Sydney, NSW, Australia
[2] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand
[3] Australian Natl Univ, Acad Unit Ophthalmol, Acton, ACT, Australia
[4] Marsden Eye Specialists, Parramatta, NSW, Australia
[5] Gladesville Retina, Gladesville, NSW, Australia
[6] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland
基金
英国医学研究理事会;
关键词
observational data; registry; data quality; audit; DATA QUALITY; INTRAVITREAL THERAPY; 12-MONTH OUTCOMES; RELIABILITY; GUIDELINES; EPITHELIUM; CATARACT; PROGRAM; AUDIT;
D O I
10.1097/IAE.0000000000002485
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the accuracy of an observational database that tracks real-world treatment outcomes for neovascular age-related macular degeneration. Methods: We audited 245 randomly sampled eyes from 189 patients with 3,356 visits from 11 doctors in the Fight Retinal Blindness! database. Sex, birth year, previous treatments received, treatment, and visual acuity were validated against the clinical notes. Error rates, the proportion of missed visits (the number of visits present in the patient record but not entered into Fight Retinal Blindness!), the level of agreement using Cohen's kappa (kappa) and intraclass correlation coefficients, and positive and negative predictive values were calculated. A visual acuity error was defined as an absolute difference of >= 5 letters. Results: The overall error rate was 3.5% (95% confidence interval: 3.1-3.9). The error rate for visual acuity was 5.1% (95% confidence interval: 4.2-5.9) and <5% for the remaining fields. The level of agreement for each field ranged from good to excellent (kappa or intraclass correlation >= 0.75). The positive predictive value and negative predictive value for visits were 99% and 89%, respectively. The proportion of missed visits was 10.2%. Conclusion: Accuracy of the Fight Retinal Blindness! database was good (>95%). The rate of missed visits was high, possibly due to the high burden of retrospective data entry or patients switching practitioners during treatment.
引用
收藏
页码:866 / 872
页数:7
相关论文
共 50 条
  • [41] Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration
    Pitlick, Jamie M.
    Vecera, Kayla F.
    Barnes, Kylie N.
    Reski, John W.
    Forinash, Alicia B.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (02) : 290 - 296
  • [42] ` Early Insight Into Neovascular Age-Related Macular Degeneration
    Dryja, Thaddeus P.
    JAMA OPHTHALMOLOGY, 2016, 134 (11) : 1281 - 1282
  • [43] Neovascular age-related macular degeneration - Potential therapies
    Chappelow, Aimee V.
    Kaiser, Peter K.
    DRUGS, 2008, 68 (08) : 1029 - 1036
  • [44] An update on the pharmacotherapy of neovascular age-related macular degeneration
    Freund, K. Bailey
    Mrejen, Sarah
    Gallego-Pinazo, Roberto
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (08) : 1017 - 1028
  • [45] The nature and frequency of neovascular age-related macular degeneration
    Iranmanesh, R.
    Eandi, C. M.
    Peiretti, E.
    Klais, C. M.
    Garuti, S.
    Goldberg, D. E.
    Slakter, J. S.
    Yannuzzi, L. A.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2007, 17 (01) : 75 - 83
  • [46] Radiation Therapy for Neovascular Age-related Macular Degeneration
    Kishan, Amar U.
    Modjtahedi, Bobeck S.
    Morse, Lawrence S.
    Lee, Percy
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (03): : 583 - 597
  • [47] Anxiety in Patients with Neovascular Age-related Macular Degeneration
    Weinstein, Orly
    Cohen, Arnon D.
    Levy, Jaime
    Zloto, Ofira
    Freud, Tamar
    Krieger, Israel
    Comaneshter, Doron
    Shemesh, Rachel
    OPHTHALMIC EPIDEMIOLOGY, 2023, 30 (03) : 286 - 292
  • [48] Gene Transfer for Neovascular Age-Related Macular Degeneration
    Campochiaro, Peter A.
    HUMAN GENE THERAPY, 2011, 22 (05) : 523 - 529
  • [49] TREATMENT PATTERNS OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Dugel, P. U.
    Arnold, R. J.
    Layton, A. J.
    VALUE IN HEALTH, 2014, 17 (03) : A149 - A149
  • [50] ANTIOXIDANT STATUS AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    SPERDUTO, RD
    ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (01) : 104 - 109